Cadrenal Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Cadrenal Therapeutics, Inc. (CVKD) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 4.12 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-08-13
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2023-12-31 was 0.00 shares.
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 428.23K shares, a 27.42% decline from fiscal 2024.
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 590.00K shares, a 92.27% decline from fiscal 2023.
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 7.63M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 11 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 4.12M shares 10-Q · filed 2026-08-13 | ||||
| 2025-12-31 | 428.23K shares 10-K · filed 2026-03-31 | ||||
| 2024-12-31 | 590.00K shares 10-K · filed 2025-03-13 | ||||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 7.63M shares 10-K · filed 2024-03-11 | |||
| 2023-09-30 | 7.63M shares 10-Q · filed 2023-11-09 | ||||
| 2022-12-31 | 1.10M shares 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |